MedTrace Logo

The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals

NCT02536846 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2022-10-03

Study results available
· View outcomes & findings →

Summary

The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.

Conditions

  • Healthy

Interventions

DRUG

Olanzapine

All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).

Sponsors & Collaborators

  • Dost Ongur

    lead OTHER

Principal Investigators

  • Dost Ongur, MD, PhD · Mclean Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-17
Primary Completion
2019-11-08
Completion
2019-11-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02536846 on ClinicalTrials.gov